Bitcoin halving
What does that mean?
$2.79T
Total marketcap
$123.35B
Total volume
BTC 49.93%     ETH 15.31%
Dominance

AstraZeneca PLC ZEG.DE Stock

125.95 EUR {{ price }} -0.198098% {{change_pct}}%
COUNTRY
Germany
Exchange
XETRA
Market Cap
195.25B EUR
LOW - HIGH [24H]
125.75 - 126.75 EUR
VOLUME [24H]
22.85K EUR
{{ volume }}
P/E Ratio
35.78
Earnings per share
3.52 EUR

AstraZeneca PLC Price Chart

AstraZeneca PLC ZEG.DE Financial and Trading Overview

AstraZeneca PLC stock price 125.95 EUR
Previous Close 134.9 EUR
Open 134.8 EUR
Bid 137.1 EUR x 30000
Ask 137.65 EUR x 30000
Day's Range 134.65 - 136.8 EUR
52 Week Range 109.35 - 140.45 EUR
Volume 3.13K EUR
Avg. Volume 3.9K EUR
Market Cap 211.48B EUR
Beta (5Y Monthly) 0.194636
PE Ratio (TTM) 48.55872
EPS (TTM) 3.52 EUR
Forward Dividend & Yield 2.73 (2.02%)
Ex-Dividend Date February 23, 2023
1y Target Est N/A

ZEG.DE Valuation Measures

Enterprise Value 237.39B EUR
Trailing P/E 48.55872
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 4.8238997
Price/Book (mrq) 5.905648
Enterprise Value/Revenue 5.415
Enterprise Value/EBITDA 15.947

Trading Information

AstraZeneca PLC Stock Price History

Beta (5Y Monthly) 0.194636
52-Week Change 15.49%
S&P500 52-Week Change 20.43%
52 Week High 140.45 EUR
52 Week Low 109.35 EUR
50-Day Moving Average 134.85 EUR
200-Day Moving Average 126.12 EUR

ZEG.DE Share Statistics

Avg. Volume (3 month) 3.9K EUR
Avg. Daily Volume (10-Days) 1.68K EUR
Shares Outstanding 1.55B
Float 1.54B
Short Ratio N/A
% Held by Insiders 0.23%
% Held by Institutions 50.59%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 2.9
Trailing Annual Dividend Yield 2.14%
5 Year Average Dividend Yield 269.00%
Payout Ratio 0.945
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 10.73%
Operating Margin (ttm) 23.09%
Gross Margin 84.30%
EBITDA Margin 33.95%

Management Effectiveness

Return on Assets (ttm) 6.42%
Return on Equity (ttm) 13.05%

Income Statement

Revenue (ttm) 43.84B EUR
Revenue Per Share (ttm) 28.32 EUR
Quarterly Revenue Growth (yoy) -4.50%
Gross Profit (ttm) 35.73B EUR
EBITDA 14.89B EUR
Net Income Avi to Common (ttm) 4.7B EUR
Diluted EPS (ttm) 2.81
Quarterly Earnings Growth (yoy) 367.09%

Balance Sheet

Total Cash (mrq) 6.46B EUR
Total Cash Per Share (mrq) 4.17 EUR
Total Debt (mrq) 32.47B EUR
Total Debt/Equity (mrq) 90.68 EUR
Current Ratio (mrq) 0.896
Book Value Per Share (mrq) 23.105

Cash Flow Statement

Operating Cash Flow (ttm) 9.71B EUR
Levered Free Cash Flow (ttm) 9.69B EUR

Profile of AstraZeneca PLC

Country Germany
State N/A
City Cambridge
Address 1 Francis Crick Avenue
ZIP CB2 0AA
Phone 44 20 3749 5000
Website https://www.astrazeneca.com
Industry Drug Manufacturers-General
Sector(s) Healthcare
Full Time Employees 83500

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc, as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Q&A For AstraZeneca PLC Stock

What is a current ZEG.DE stock price?

AstraZeneca PLC ZEG.DE stock price today per share is 125.95 EUR.

How to purchase AstraZeneca PLC stock?

You can buy ZEG.DE shares on the XETRA exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for AstraZeneca PLC?

The stock symbol or ticker of AstraZeneca PLC is ZEG.DE.

Which industry does the AstraZeneca PLC company belong to?

The AstraZeneca PLC industry is Drug Manufacturers-General.

How many shares does AstraZeneca PLC have in circulation?

The max supply of AstraZeneca PLC shares is 1.55B.

What is AstraZeneca PLC Price to Earnings Ratio (PE Ratio)?

AstraZeneca PLC PE Ratio is 35.78125000 now.

What was AstraZeneca PLC earnings per share over the trailing 12 months (TTM)?

AstraZeneca PLC EPS is 3.52 EUR over the trailing 12 months.

Which sector does the AstraZeneca PLC company belong to?

The AstraZeneca PLC sector is Healthcare.